The new anti-cancer drug ibrutinib (Imbruvica), developed by the J & J pharmaceutical company is significantly more effective than standard chemotherapy for leukemia. This is evidenced by the results of clinical studies published in The Daily Mail.
During the trial, some patients with chronic lymphocytic leukemia received ibrutinib, and some patients received chemotherapy. It turned out that in the first group the survival rates were 90%, in the chemotherapy group - 81%. The researchers note that in the group of participants receiving ibrutinib, remission rates were in four out of ten patients, in the chemotherapy group - four out of a hundred.
https://www.medixocentre.com/ibrutinib-140-mg ↗